





CENTER FOR **HOPE** HEALTH OUTCOMES & POPULATION EQUITY





Planning for Diversity: BeatPain Utah

Julie M. Fritz, PT, PhD David W. Wetter, PhD

Disparities in Pain Prevalence and Management



From 1999 to 2016, the rate of opioid mortality increased 4.5 times faster in rural versus metro communities




Persons residing in low-income communities have a 63% higher odds of receiving a prescription opioid for a new back pain diagnosis



Use of self-management and nonpharmacologic pain treatments are lower in rural versus non-rural settings, lower for persons of Hispanic/ Latino ethnicity


Gebauer S, et al. *J Am Board Fam Med*. 2017;30(6):775-783. Monnat and Rigg, The Opioid Crisis in Small Town America. Available at: <u>https://carsey.unh.edu/publication/opioid-rural-smalltown-us</u> García MC, et al. Morbidity Mortality Weekly Report. January 18, 2019, 68(2);25–30

Disparities in Pain Prevalence and Management




FROM: (Dahlhamer J et al, MWMR Morb Mortal Weekly Rep, 2018)


Share of the Population Identifying Outside Non-Hispanic White



Note: This is sample-based survey data.

Source: U.S. Census Bureau, American Community Survey Ranking Tables. Calculations by Kem C. Gardner Policy Institute.





Frontier Counties as defined by Public Law 94-171 are those counties with a population density of fewer than 7 people per square mile.

Center for HOPE Mission, Vision, Foci

Purpose: Serve as a *research infrastructure* and bridge between scientists and community organizations (e.g., health care, government, education, nonprofits, faith based, social services, tribal) throughout Utah and the Mountain West. Utilize strategic focused partnering for community engagement and sustainability.

Mission: Bring communities and researchers together to **create long-term solutions** to prevent cancer, chronic and infectious disease, and improve health among underserved populations.

Vision: Equity in cancer and chronic disease incidence, morbidity, and mortality in Utah/Mountain West.

Major Research Foci:

- Health inequities
- Implementation and dissemination of evidence-based interventions
- Behavioral interventions
- Low socioeconomic status, racial/ethnic minority, rural/frontier

Training Mission

• Train scientists/researchers to address health inequities and social justice



Strategic, Focused Partnering for Community Engagement and Sustainability

Partnership Categories

- **Network Partner**: Maintain contact for information sharing, dissemination, recruitment.
- **Development Partner**: Developing relationship toward potential projects/proposals; communicate on shared priorities and opportunities.
- Research Partner: Long-term, formal partnership for research projects or programs; shared decision-making.





13 Utah health centers^{*} operate **54 clinics** in urban and rural communities and provide care to more than **167,000 people** annually.

Racially/Ethnically Diverse

- 49% Hispanic/Latino Ethnicity
- 9% American Indian/Alaska Native

Low Socioeconomic Status

- 66% < Federal Poverty Level
- 49% Uninsured

Rural/Frontier (28 Clinics in Total)

- 10 clinics in frontier counties (<6 people per square mile)
- 18 clinics in rural counties (6-100 people per square mile)



Research Partnership

Association for Utah Community Health (AUCH) Utah Department of Health (UDOH) Utah Community Health Centers (CHCs) Center for HOPE/University of Utah/Huntsman Cancer Institute

- Funded Grants
 - QuitSMART Utah (PCORI Pragmatic Trial) \$9.5M
 - HRSA Health Information Technology (AUCH leads)
 - Colorectal Cancer Screening (CDC) ~\$3.5M
 - BeatPain Utah (NINR) ~\$3M
 - RADXU COVID-19 (NCATS) ~\$5M
 - HPV Vaccination (ACS) ~\$900K
- <u>Pending Grants</u>
 - RADxUP COVID- 19 Schools (NIH)
 - Social Determinants of Health/Obesity (NIH)
- Planned Grant Submissions
 - RADxUP COVID- 19 Phase II (NIH)
 - Low Dose CT Screening for Lung Cancer (NIH)
 - Adolescent Vaping (NIH)






CENTER FOR HOPE

HEALTH OUTCOMES & POPULATION EQUITY



Community – Engaged Dissemination and Implementation Research



Schlechter, C. R. et al. Application of Community – Engaged Dissemination and Implementation Research to Improve Health Equity. (under review)

Partnership Characteristics

- Shared Goals
 - All of our research projects have been driven by the priorities of our community partners
- Mutual Respect of Expertise
 - Patient and Study Advisory Committees
 - Primary Care Association team member from AUCH embedded at the Center for HOPE
- Shared Resources and Data
 - All projects include bidirectional communication with respect to patient data (e.g., immunization registry)
 - Utah Department of Health has shifted funding and provided resources/data to create synergy with the funded research projects (e.g., providing tobacco cessation medications for uninsured; identifying COVID hotspots to target)
 - Projects have provided funding to AUCH to tie together Utah's 13 CHCs via a Population Health Management tool

Designing for Sustainability

- Health Information Technology as a Foundation
 - Work with CHC EHRs and EHR vendors to create solutions that can be immediately disseminated and implemented by other users of those EHRs
 - Population Health Management tools to tie CHC systems together to enable identification of patient cohorts and "campaigns" (e.g., texting) to address patient needs
- Community Health Workers/Health Educators/Patient Navigators
 - Many CHCs have Community Health Workers on staff
 - Association for Utah Community Health has Community Health Workers on staff
- Utilize Existing Evidence-Based Interventions (EBIs)/Resources
 - Linkages for primary prevention utilize existing EBIs (e.g., Tobacco Quitlines, Diabetes Prevention Programs)
 - Linkages for screening/testing/vaccination collaborate with state programs (e.g., colorectal, breast and cervical, COVID, HPV)

SUMMARY

- Consider the different categories of partnerships
- Research opportunities arise from the priorities of community partners
- Mutual respect for expertise and bidirectional communication
- Designing for sustainability from the outset

Grand Rounds Diversity Workshop Series

Session 1: Planning for Diversity: Stakeholder Engagement and Site Selection to Maximize Diversity

Gloria Coronado, Distinguished Investigator Amanda Petrik, Sr. Research Associate



Presentation Agenda


STOP CRC Pragmatic Study in Community Health Centers

Stakeholder Engagement

Patient Engagement

Organizational Engagement

- PROJECT LOCATIONS



Pragmatic Implementation Research determines the best approach for the population.




Stakeholder engagement supports pragmatic research



- Builds partnerships based on mutual respect
- Grounds the research in the contributions of community organizations, advocates, stakeholders
- Conducts research that gives policy-makers and implementers access to detailed data to guide the design and delivery of care/services
- Leverages local knowledge -- informed by advisory group
- Produce results that are meaningful
- Shares results that are tailored to population subgroups, in a non-technical way, without oversimplification

CRC Screening Disparities



BRFSS 2018

The STOP CRC pilot was more effective in the Hispanic population.








Stakeholder engagement is critical.



Virginia Garcia Memorial HEALTH CENTER



Clinic		% Hispanic aged 50-74	% aged 50-74 who obtained FIT or FOBT
#1	898	73	3.7
#2	1562	52	3.9
#3	1495	31	5.2
#4	1235	38	7.6

Stakeholder engagement leads to trust.



• Leadership Engagement

Patient Council Engagement



Patient and clinical engagement creates sustainability.



Patient feedback improved patient facing materials.

Intended purpose

The InSure* ONE" test detects if there is any hidden blood in your stool. The presence of blood may be a sign of lower gastrointestinal disorders that should be treated. The sample is collected in the privacy of your home and the test is then developed at laboratories or medical professional offices. The InSure* ONE" test is for in vitro diagnostic use only.

IVD Medical Device

InSure* ONE" test complies with the IVD Medical Device Directive 98/79/EC and carries the CE mark.

Methodology

InSure" ONE" test is used to detect bleeding in the lower intestine, Colorectal diseases, such as polyps and colitis, leak small amounts of blood into the lower intestine. If there is hidden blood in your stool, it is then passed from the stool to the toilet bowl water. The InSure* ONE" kit contains everything required to collect two toilet bowl water samples from one stool to test if there is blood in the sample. The collection is simple, does not require handling of the stool and is completed in the privacy of your bathroom.

Composition

For in vitro diagnostic use

Preparing to collect samples

· Eating fruits and vegetables can increase test accuracy.

. Check the "Kit Contents" list to be sure you have all the components.

· If you have cleaners or bluing agents in your toilet bowl or tank,

· Read all instructions before beginning your test. . You do not have to avoid any foods or medications.

remove them and flush the tailet twice

The test kit contains no reactive ingredients.

Kit contents Instructions for Use

. Test Card Brush Kit consisting of two brushes and two waste bags Return envelope · Reply form with label

Storage and handling

notion to make the states of children

Instructions

for Use

tampered with in any way

The Test Card should be stored at room temperature. Protect from heat and direct sunlight. Use the kit prior to expiration date printed on the Test Card.

Limitation of the procedure

This test detects human blood in your stool. There are many gastrointestinal conditions that may cause blood in your stool. If you receive a "positive" test, more testing and evaluation by a physician is necessary. This test does not replace your regular physical or rectal exam by your physician. A "negative" test result means that no human blood was found in the sample. However colorectal lesions, including some polyps and colorectal cancers, may bleed intermittently, or not at all. Additionally, blood may not be uniformly distributed in or on the stool and a test result may be negative even when blood or a lower gastrointestinal disease is present.

Read all instructions before beginning your test.



Take these instructions. Brush Kit and Test Card

· Flush the toilet BEFORE your bowel movement

STEP 1

into the bathroom

BRUSH

STEP 4

the stool.



DISCARD

STEP 2

· After your bowel movement, DO NOT PLACE USED TOILET PAPER IN THE TOILET BOWL. Instead, use one of the blue waste bags provided. DO NOT FLUSH the toilet after your bowel movement.

LIFT

STEP 3 · Lift the flap marked "LIFT HERE FOR SAMPLE" on the Test Card to uncover the small white squares marked "1" and "2."



August D-30855 Langenhagen IT slisht rangednagne.

HdmD eqoru3 ibm EC BEb

A2U 75880 LV nosib3 , avA boowma7 852 Enterix Inc., A Clinical Genomics Inc. Company



burantoid 5 SHARP IESTED III SUBSURIED ON MA INT

Warnings and precautions Some conditions may cause a wrong result;

· Collection Kit is damaged, dirty or appears to have been

. You have any bleeding cuts or wounds on your hands

· You have blood in your urine, or you see blood in the toilet bowl.

you should not perform this test if:

. The Test Card has passed its expiration date.

· You have hemorrhoids that are bleeding,

. Your toilet bowl water is saltwater or rusty.

In this case, contact your doctor.

SAUTON NOT THE THEFT WAS косрамаў пот вол

smand and to ano 4q paravos si tanbord sid T turnerned

pasn sloquks

InSure ONE



STEP 5 · Using one of the blue brushes, gently brush the · Transfer a sample of the WATER ONLY by gently dabbing the bristles of the brush onto the small surface of the stool for about 5 seconds If the stool is loose, simply stir the water around white square labeled "I" on the Test Card for about 5 seconds (some staining of the square may occur) · Discard used brush in one of the blue waste bags · Remove the brush from the water and gently shake it and throw away once to remove excess water and any clumps of stool



· Using the second blue brush, repeat step 4 and transfer a second WATER sample to the test card by gently dabbing the bristles of the brush onto the small white square labeled "2" for about 5 seconds · Discard used brush in the other blue waste bag and throw away in your trash



Print your name, date of birth, and the date the

sample was collected on the removable label

REMEMBER TO INCLUDE DATE OF

SAMPLE COLLECTION.

STEP 8

· Complete the Reply Form. · Place the Test Card and Reply Form in the postagepaid mailing envelope provided. + If your medical professional or the laboratory provided you with a pre-printed test requisition form include the form also in the return envelope



Return to the indicated laboratory or medical professional office either by mail or personal delivery. Test Card must be returned to the indicated laboratory or medical professional as soon as possible and within 14 days of sample collection. The results will be provided by your medical professional



· Peel off the label and use it to reseal the flap




+ It is three days before, during or three days after your menstrual period.


Copyright © 2017 Enterix Inc. All rights reserved. Covered by U.S. Patents including Patent Nos. 6.221.678. 6.271.046. 6.869.804. & 6.977.173

























© 2018, Kaiser Permanente Center for Health Research. Funding provided by the National Institute on Minority Health and Health Disparities (Award U01MD010665). Created in conjunction with AtaMed Health Services.





Funding provided by the Centers for Disease Control and Prevention (Award Number U48 DP004998) and the Jacobschn Fund for Excellence Adapted with permission from: KAISER PERMANENTE CENTER FOR IHEALT RESEARCH
















Funding provided by the Ontario Ministry of Health and Long-Term Care Adapted by Cancer Care Ontario with permission from: KAISER PERMANENTE CENTER FOR HEALTH RESEARCH (NH grant number: UH3 CA188640) and the UCSF Health Outcomes Policy & Economics (HOPE) Research Program

CHR 60660 03/09/2020

Adapt the project to address barriers.





OCHIN

lyA

Organizational Engagement Strategies

ADVISORY BOARD

PLAN-DO-STUDY-ACT CYCLES

STOP CRC Advisory Board identified need for policy changes



- 14-member board comprised of
 - Health center leaders
 - Patient advocates
 - Legislators
 - Community organizations leader
- Meeting schedule
 - Annual full-day in-person meeting
 - Monthly, then quarterly meetings
- Advisory board continues to meet

Advisory board paved the way to policy changes

Oregon Incentives Oregon passed passed metric for legislation to legislation to coordinated eliminate make a care 2013–2019 organization screéning out-of-- 2013 colonoscopy pocket costs 2019 (~90% for follow-up remain a of Medicaid colonoscony screening


Child and Adult Core Set Stakeholder Workgroup: 2022 Annual Review Voting Meeting – Day 3, May 2021

Addition: Colorectal Cancer Screening

Description	Percentage of patients 50 to 75 years of age who had appropriate screening for colorectal cancer.				
Measure steward	National Committee for Quality Assurance (NCQA)				
NQF number (if endorsed)	0034				
Measure type	Process				
Recommended to replace	No				
current measure?					
Data collection method	Administrative, hybrid, and HEDIS® Electronic Chinical Data Systems (ECDS).				
	(Note: ECDS includes data free as a sistence claims, electronic health records, case management systems, a				
	health information exclusion estimation registries. NCQA has proposed transitioning this measure to ECDS only				
	reporting starting temes urement year 2024 and is currently assessing public comment regarding this proposal.)				
Denominator	Members 51 to 75 years of age as of December 31 of the measurement year.				
Numerator	Members with one or more screenings for colorectal cancer. Any of the following meet criteria:				
	 Fecal occult blood test (FOBT) during the measurement year. For administrative data, assume the required 				
	number of samples were returned, regardless of FOBT type.				
	 Flexible sigmoidoscopy during the measurement year or the four years prior to the measurement year. 				
	 Colonoscopy during the measurement year or the nine years prior to the measurement year. 				
	 Computed tomography (CT) colonography during the measurement year or the four years prior to the measurement year. 				
	 Fecal immunochemical DNA (FIT-DNA) test during the measurement year or the two years prior to the measurement year. 				



Plan–Do– Study–Act engaged health centers to address challenges




Reviewed Partnered with a Stuality Metrovitenteent applicator, teaidershipPDSA ared teams of **EMR** each health screening PDSA plan (due withing month) provider $CIIN(\Delta)$ PDSA results (due 3 – 6 months later) All sites presented findings at Advisory **Board meeting**

STOP CRC approach to using **PDSA** cycles

One health center used a PDSA to test FIT reminders

- 2,722 patients identified in 4 clinics and mailed a FIT kit;
- 2232 patients randomized to one of several reminders




Coronado et al. 2017

KAISER PERMANENTE®

Success of reminders for a mailed FIT program

FIT return rates among patients who prefer Spanish versus English



KAISER PERMANENTE®

Reactions to PDSA used in research

Providers and clinic staff had favorable reactions

"But the [PDSA] process itself, we kind of do that organically already without calling it a PDSA. So now it's nice to have a form and a template that we can work by so that we can get feedback ... and come up with questions like 'What about if we did this?' or 'Who's going to do that?' So it's good to have that template to work from."



— Quality Improvement Manager



Lessons learned

In STOP CRC, we selected our most diverse clinic for the pilot phase.

We refined our materials using clinic and patient feedback; these materials are being used by KP and dozens of other health systems.

We assembled an advisory board that addressed policy barriers, this provided data for national policy changes.

We guided health centers to conduct Plan-Do-Study-Act Cycles, this allowed up to understand implementation barriers.

Building partnerships take time; staff turnover is a key challenge.

Resources

www.MailedFIT.org

A KAISER PERMANENTE. Center for Health Research	Home	About	Research	News	Contact	
--	------	-------	----------	------	---------	--

Research > Our People > Gloria D. Coronado > mailedfit

Mailed FIT - Resources to Optimize Colorectal Cancer Screening



We, at the Center for Health Research, and with our partners, are trying to understand how to most effectively raise colorectal cancer screening rates across the country, in a variety of settings, through a diverse set of research projects. Colorectal cancer is the second-leading cause of cancer deaths. Early detection saves lives, yet too few adults are screened regularly.

Screening rates are particularly low for certain groups of people. Working with FQHCs allows us to deliver our program to those who need it the most.




Q

FIT Instructions

3. Pee and Flush

Gloria Coronado, PhD

🖂 Gloria.D.Coronado@kpchr.org





How to complete the FIT

This video will show you how to complete the simplest at-home screening method called the FIT test.

Acknowledgement

S

- Kaiser Permanente Center for Health Research, Portland, OR
 - Gloria D. Coronado, PhD, Pl
 - Erin M. Keast, MS, Analyst
 - William M. Vollmer, PhD, Statistician Co-I
 - Richard Meenan, PhD, Co-I
 - Jennifer Schneider, MA, Co-I
- National Cancer Institute, Rockville MD
 - Steve H. Taplin, MD, MPH
 - Russ Glasgow, PhD
 - Jerry Suls, PhD
 - Erica Breslau, PhD
- Kaiser Permanente Washington, Research Institute, Seattle, WA
 - Beverly B. Green, MD, MPH
- OCHIN, Portland, OR
 - Scott Fields, MD